In the dynamics of the lower urinary tract, further knowledge has been gained above all concerning distribution and characterization of the adrenoceptors. Moreover recent results of both experimental and clinical research have focused attention on the role of the peripheral adrenoceptors in seminal ejaculation and related disorders. On the other hand, norepinephrine has been accepted as the principal neurotransmitter in the control of penile detumescence and flaccidity. The rationale of applying such knowledge to minctional, erective and ejaculative disorders is discussed on the basis of a literature review as well as of our own studies on the topic.
AlbertiC., PiacentiniL., SacchiniP., CortelliniP.: Nuove acquisizioni sull'assetto recettoriale del tratto urinario inferiore. Minerva Urol. Nefrol., 43: 245–253, 1991.
4.
AlbertiC., SacchiniP., CortelliniP.: Neuromodulazione centrale e periferica dell'eiaculazione. Minerva Urol. Nefrol., 43: 253–263, 1991.
5.
AlbertiC., FrattiniA., FerrettiS.: Ruolo dell'ossido d'azoto nel meccanismo erettivo. Minerva Urol. Nefrol., 45: 49–54, 1993.
6.
AwadS.A., BruceA.W., Carro-CiampiG.: Distribution of α and β-adrenoceptors in human urinary bladder. Br. J. Pharmacol., 50: 525–529, 1947.
7.
CaineM., RazS., ZeiglerM.: Adrenergic and cholinergic receptors in the human prostate and bladder neck. Br. J. Urol., 47: 193–202, 1975.
8.
LarsenJ.J.: α and β-adrenoceptors in the detrusor muscle and bladder base. Br. J. Pharmacol., 65: 215–222, 1979.
9.
KaumanA.J.: Is there a third heart β-adrenoceptor? Trends Pharmacol. Sc., 10: 316–20, 1989.
10.
ChappieG.R., AubryM.L., JamesS.: Characterization of human prostatic adrenoceptors using pharmacology receptor binding and localization. Br. J. Urol., 63: 487–496, 1989.
11.
KunisawaY., KawabeK., NijimaT.: A pharmacological study of α-adrenoceptors subtypes of human urinary bladder base and prostatic urethra. J. Urol., 134: 396–398, 1985.
12.
ShapiroT., TsitlikJ.E., LeporH.: α2-adrenergic receptors in canine prostate: biochemical and functional correlations. J. Urol., 137: 565–570, 1987.
13.
HaradaT., CostantinouC.E.: The effect of α2-agonists and antagonists on the lower urinary tract of the rat. J. Urol., 149: 159–164, 1993.
14.
WeissR., TomasulaJ.J., SotolongoJ.R.Jr.: The effect of an α2-agonist on bladder function and cord histology after spinal cord injury. J. Urol., 144: 1527–32, 1990.
15.
BartschG., MüllerH.R., OberholzerM., RohrH.P.: Light microscopic stereological analysis of the normal human prostate and BPH. J. Urol., 122: 487–94, 1979.
16.
ShapiroE., BecichM.J., HartantoV., LeporH.: The selective proportion of stromal and epithelial hyperplasia is related to the development of symptomatic BPH. J. Urol., 147: 1293–97, 1992.
17.
LeporH., ShapiroE.: Characterization of α1-adrenoceptors in human BPH. J. Urol., 132: 1226–1230, 1984.
18.
CaineM., PfauA., PelbergS.: The use of α-adrenergic blockers in benign prostatic obstruction. Br. J. Urol., 138: 979–983, 1976.
19.
CaineM., PerlbergS., MeretycS.: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br. J. Urol., 51: 551–54, 1978.
20.
MartoranaG., GibertiC., DamonteP.: The effect of prazosin in benign prostatic obstruction. IRCS Med. Sci., 12: 11–13, 1984.
21.
LeporH., KnappD., LaddyA.R.: The safety and efficacy of terazosin for the treatment of BPH. Int. J. Clin. Pharmacol. Ther. Toxicol, 27: 392–397, 1989.
22.
LeporH., HenryD., LaddyA.R.: The efficacy and safety of terazosin in the treatment of symptomatic BPH. Prostate, 18: 345–355, 1991.
23.
LeporH.: Role of long-acting selective α1-blockers in the treatment of BPH. Urol. Clin. North Am., 17: 651–659, 1990.
24.
JardinA., BensadounH., Delauche-CavallierM.C., AttaliP.: BPH-ALF Group: alfuzosin for treatment of BPH. Lancet, 337: 1457–1461, 1991.
25.
MartelliA., PacificoP., CasadeiG.: ALF Cooperat. Group “Effect of alfuzosin on quality of life in BPH patients: preliminary results”. Eur. Urol., 24(suppl.): 28–33, 1993.
26.
Di SilverioF., The use of terazosin in the treatment of BPH: Italian experience. Br. J. Urol., 70(suppl.): 22–26, 1992.
27.
ArtibaniW., TrabucchiM., BensadounH.: Gli α1-litici in Urologia. Aggiornamento Medico, 1(suppl.): 1–8, 1993.
28.
Lefèvre-BorgF., LechaireJ., O'ConnorS.: In vivo uro-selectivity of alfuzosin compared to prazosin and terazosin. Br. J. Pharmacol., 106: 84–86, 1992.
29.
PerlbergS., CaineM.: Adrenergic response of bladder muscle in prostatic obstruction. Urology, 20: 524–527, 1982.
30.
RestorikJ.M., MundyA.R.: The density of cholinergic and α- and βadrenergic receptors in the normal and hy-perreflexic human detrusor. Br. J. Urol., 63: 32–37, 1987.
31.
TanaghoE.A.: Role of α-blockers in bladder oudet function. In: “Proceedings on prostate gland and α1-blockers”.Excerpta Medica, 307–313, 1989.
32.
CockettA.T., AsoT., DenisL.: Recommendations of the International Consensus Committee on BPH. S.C.I., pagg. 279–288, Parigi, 1991.
33.
BarryM.J., FowlerF.J., O'LearyM.P.: The measurement Committee of the American Urological Association: correlation of the AUA symptom index with self-administered version of the Madsen-Iversen, Boyarsky and Maine medical assessment program symptom indexes. J. Urol., 148: 1558–1563, 1992.
34.
FowlerF.J.Jr., BarryM.J.: Quality of life assessment for evaluating BPH treatments. Eur. Urol., 24(suppl. 1): 24–27, 1993.
35.
HansenB.J., HaldT.: Review of current medical treatment of BPH. Eur. Urol., 24(suppl. 1): 41–49, 1993.
36.
PentlandB., AndersonD.A., CritchleyJ.A.: Failure of ejaculation with indoramine. Br. Med. J., 282: 1433–1440, 1981.
37.
ShilonM., PazG.F., HommonaiZ.T.: The use of phenoxibenzamine in premature ejaculation. Fert. Steril., 42: 659–665, 1984.
38.
ClarkJ.T., SmithE.R., DavidsonJ.M.: Evidence for the modulation of sexual behavior by α-adrenoceptor in rats. Neuro-Endocrinology, 41: 36–42, 1985.
39.
AdaikanP.G., RatnamS.S.: Pharmacology of penile erection in humans. Cardiovasc. Intervent. Radiol., 11: 191–194, 1988.
40.
VanhoutteP.M.: The end of the quest. Nature, 327: 459–460, 1987.
41.
RajferJ., AronsonW.J., BushP.A.: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic-noncholinergic neurotransmission. New Engl. J. Med., 326: 90–94, 1992.
42.
DiedericheW., StiefC.G., LueT.F., TanaghoE.A.: Norepinephrine involvement in penile detumescence. J. Urol., 143: 1264–1270, 1980.
43.
Saenz de TejadaL., GoldsteinI., AzadzoiK.: Impaired neurogenic and endothelium-depending relaxation of human penile smooth muscle from diabetic men with impotence. New Engl. J. Med., 320: 1025–1030, 1989.
44.
StiefC.G., HolmquistF., AllhoffE.P.: Preliminary report on the effect of the NO-donor SIN-1 on human cavernous tissue in vivo. World J. Urol., 9: 237–241, 1991.
45.
PorstH.: PGE, and the NO-donor linsidomine for erectile failure. J. Urol., 149: 1280–83, 1993.
46.
LernerS.E., MelmanA., ChristG.J.: A review of erectile failure. J. Urol., 149: 1280–1283, 1993.
47.
BistolfiF.: Il sistema bioconduttivo connessionale. Radiol. Med., 80: 203–206, 1990.
